SNCA and Parkinson disease: In addition, the multicenter, randomized, double-blind, placebo-controlled NCT05287503 trial (Ambitious study) is investigating whether the prolonged administration of high-dose oral ambroxol is able to change GCase activity and α-synuclein CNS levels and to reduce the progression of cognitive decline and motor disability in a cohort of 60 PD-GBA patients.